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Outbreak of sterile peritonitis among continuous cycling perito-
neal dialysis patients.
Background. Approximately 30,000 patients receive peritoneal
dialysis in the United States. In August 1996, several dialysis
centers from different states reported sterile peritonitis among
CCPD patients using sterile peritoneal dialysis solution (PDS)
from a single manufacturer. The manufacturer recalled 53 lots of
PDS that had passed established industry guidelines and Food
and Drug Administration (FDA) approved quality control tests
[including endotoxin levels ,0.5 endotoxin units (EU)/ml], but
had pre-sterilization bacterial colony counts .1 cfu/ml.
Methods. At one outpatient dialysis center, Hospital of the
University of Pennsylvania (HUP), we conducted a retrospective
cohort study of all CCPD patients treated during July 15 to
August 30, 1996. A case-patient was defined as any HUP patient
with culture-negative peritoneal fluid with a white blood cell count
.100/mm3, cloudy peritoneal fluid, and/or abdominal pain. PDS
and tubing were cultured for bacteria and assayed for endotoxin.
Results. Overall, 14 of 28 patients had sterile peritonitis. The
only risk factor identified was exposure to $1 lot of recalled PDS
(14 of 22 vs. 0/6, P 5 0.02); the more recalled lots received, the
higher the attack rate (P 5 0.0001). Five of 47 PDS bags had
detectable endotoxin; recalled lots were more likely to have
measurable endotoxin than nonrecalled lots (5/19 vs. 0/17, P 5
0.05). When case-patients resumed CCPD using PDS from non-
recalled lots, no further cases were reported.
Conclusions. Our results suggest that this outbreak was caused
by intrinsic PDS contamination with endotoxin. Pre-sterilization
colony counts may be an important quality control indicator for
CCPD fluids in conjunction with endotoxin levels.
At the end of 1995, approximately 200,000 patients with
end-stage renal failure were receiving dialysis in the United
States [1]. Of these, 21,563 (10.8%) were treated with
continuous ambulatory peritoneal dialysis (CAPD) and
10,113 (5.1%) with continuous cycling peritoneal dialysis
(CCPD). Peritonitis is a major complication of peritoneal
dialysis. The signs and symptoms of peritonitis associated
with peritoneal dialysis include one or more of the follow-
ing: cloudy peritoneal dialysis effluent, abdominal pain,
nausea, vomiting, fever, and chills. Peritonitis usually is
caused by bacterial infection, but sterile peritonitis does
occur. Sterile peritonitis, which also is described as aseptic,
chemical, or culture-negative peritonitis, is usually caused
by a chemical or foreign body irritant. In 1977, an outbreak
of sterile peritonitis among peritoneal dialysis patients was
attributed to intrinsic endotoxin contamination of dialysate
solution, where suspected lots had endotoxin levels in the
range of 2 to 2.5 endotoxin units (EU)/ml [2]. Other
reported causes of sterile peritonitis include vancomycin,
amphotericin B, and methylene blue [3–5]. In this report,
we describe an outbreak of sterile peritonitis occurring in
CCPD patients.
Background
From July 1 through August 15, 1996, an outpatient
dialysis center at Hospital University of Pennsylvania
(HUP) noted an increased number of CCPD patients with
peritonitis. All patients received CCPD at home and re-
ported using 5-liter bags of dialysis solution and tubing sets
supplied by a single manufacturer (Fresenius Medical Care,
North America, formerly called Fresenius, USA Inc., Og-
den, Utah, USA).1 When an initial investigation at HUP
did not identify the cause of the outbreak, assistance was
requested from the Hospital Infection Program, Centers
for Disease Control and Prevention (CDC). The objectives
of our investigation were to confirm the presence of anKey words: epidemic, CCPD, home dialysis, dialysate contamination,
infection, endotoxin.
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outbreak, assess risk factors, and implement control mea-
sures to terminate the outbreak. During the same period
that the outbreak occurred at HUP, CDC received reports
of similar episodes of sterile peritonitis among CCPD
patients using peritoneal dialysis solution (PDS) from the
same manufacturer at other outpatient dialysis centers in
several states (that is, California, Michigan, North Caro-
lina, New Jersey, New York, Wisconsin). On August 16,
1996, the company recalled 53 lots of PDS.
METHODS
Case definition and ascertainment
A case-patient was defined as any patient receiving
CCPD at HUP outpatient dialysis center from July 1
through August 15, 1996, (that is, the epidemic period) with
(a) cloudy peritoneal fluid or abdominal pain; (b) perito-
neal fluid white cell count . 100 mm3; and (c) negative
peritoneal fluid cultures for bacteria or fungi. Case-patients
were identified from chart and laboratory record review.
Epidemiologic studies
To determine whether an outbreak had occurred, the
rates of sterile peritonitis per patient month were com-
pared in all HUP peritoneal dialysis patients during the
epidemic and pre-epidemic (January 1995-June 1996) pe-
riods.
To identify risk factors for sterile peritonitis, we con-
ducted a retrospective cohort study of all CCPD patients
treated at HUP during the epidemic period. We assessed
demographic factors, geographic location of the patient’s
home, type and lot number of dialysis solution and tubing,
dialysis procedures and protocols, type of dialysis machines,
and medications received. The lot numbers for the dialysis
solution and tubing sets were provided by the manufac-
turer, and, in some instances, directly from patients
through phone interviews and/or home visits.
We reviewed the manufacturer’s manual, guidelines, and
instructions for CCPD provided by the staff at the dialysis
center. The nursing staff at HUP outpatient dialysis center
conducted a simulated instruction class to illustrate how
patients are taught to perform CCPD.
Laboratory evaluation
Peritoneal fluid cell counts and cultures were performed
at the HUP microbiology laboratory; 5 to 10 ml of perito-
neal fluid were cultured for bacteria and fungi using the
Bactec System (Becton Dickinson, Towson, MD, USA).
Tubing sets and samples of dialysis fluid were obtained
from the patients, HUP, and the manufacturer and sent to
CDC for endotoxin assay by the limulus lysate turbidimetric
method [6].
Manufacturers’ phone survey
During July to August 1996, personnel from the manu-
facturer contacted by phone all dialysis centers caring for
patients who had, according to company records, received a
recalled lot of PDS. For each patient, data were collected
on the lots received, geographic region, dialysis center,
shipment dates, whether peritonitis had occurred, and, if
so, the date of onset.
Statistical analysis
Data for the cohort study at HUP were collected on
standardized forms, entered, and analyzed using Epi-Info
6.02 [7]. Preliminary data collected by the manufacturer
during the phone contact of the dialysis centers were
entered into a computer file and analyzed using the SAS for
personal computers (SAS Institute, Inc., Cary, NC, USA).
Categorical variables were compared using the Chi-square
or the Fisher’s exact test. Relative risk (RR) and 95%
confidence intervals were calculated. Multivariate analyses
were performed by constructing logistic regression models.
RESULTS
Epidemiologic studies
The rate of sterile peritonitis at the HUP outpatient
dialysis center was significantly higher in the epidemic
versus the pre-epidemic period (14 episodes during 45
patient months vs. 3 episodes during 525 patients months,
P , 0.001).
The 14 epidemic-period case-patients ranged in age from
24 to 64 (median 49) years; five (36%) were female, ten
(71%) were black, and four (29%) were white. None of the
14 case-patients had an episode of peritonitis in the pre-
ceding three months. Case-patient signs and symptoms
included cloudy peritoneal fluid (N 5 13; 93%), abdominal
pain (N 510; 71%), chills (N 5 6; 43%), fever (N 5 4;
29%), nausea and vomiting (N 5 3; 21%), and/or exudate
around the catheter site (N 5 4; 29%). Ten (71%) case-
patients first presented to the dialysis center, while four
(29%) presented to the emergency room. The peritoneal
fluid cell count ranged from 114 to 999 (median 5 283)
cells/mm3.
There was no significant association between sterile
peritonitis and gender or exposure to any one of 12
separate lots of dialysis tubing (Table 1). Exposure to either
of two specific lots (lots A and B) of PDS had a relative risk
.2, but the results were not statistically significant. How-
ever, receipt of $ 1 lot of recalled dialysis fluid was a
significant risk factor for sterile peritonitis (14 of 22 vs. 0 of
6, P 5 0.016). Also, the more recalled lots received by a
patient, the higher the attack rate (Table 1). When case-
patients resumed CCPD using PDS from non-recalled lots,
they had no further symptoms.
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Results of manufacturer’s phone survey
Of the 53 recalled lots of PDS, 19 were sent to another
supplier and data on their clinical effect are not available.
The remaining 34 lots were distributed directly by the
manufacturer to CCPD patients at 515 dialysis centers. Of
the 1,905 patients who received $ 1 recalled lot of PDS,
260 (13.6%) were reported to have sterile peritonitis.
Of the 34 lots, 12 were significantly associated with sterile
peritonitis in univariate analysis. Because some of the
patients received .1 lot, a logistic regression model was
constructed, and 9 lots remained as independent risk
factors for sterile peritonitis (Table 2).
The phone survey indicated that sterile peritonitis oc-
curred in 6 of 24 (25%) HUP CCPD patients who had
received PDS from subsequently recalled lots. In contrast,
our on-site investigation documented a 14 of 22 (64%)
attack rate.
Procedure review
Patients received 15 to 30 boxes (each box contained two
5-liter bags) of dialysis solution and 4 to 10 boxes of tubing
sets per delivery, depending on the patient’s individual
needs. All on-site CCPD patients at HUP used the Frese-
nius Freedom Cycler P. D. dialysis machine. Patients were
trained to perform CCPD at the dialysis center by the
nursing staff for one to two weeks. Patients were instructed
to wash their hands for three minutes before the start of
dialysis, wear a mask during set-up for dialysis, and main-
tain sterility during connection. The patients were trained
to examine their dialysis solution bags before use for any
discoloration or leakage and to check the expiration date.
Patients were instructed to follow the manufacturer’s pro-
tocol for setting-up the machine, initiating dialysis, and
setting-up equipment for the next treatment. These prac-
tices were reinforced at each patient clinic visit. Neither
patients nor staff reported any changes from or non-
adherence to these procedures.
Microbiology
All cultures of case-patients’ peritoneal dialysis fluid
were negative for bacteria. Peritoneal fluids from 10 case-
patients also were cultured for fungi and mycobacteria; all
were negative. Some patients had initial cultures at outside
hospitals/emergency facilities that did not look for fungi
and mycobacteria.
Five of 36 lots of PDS tested had measurable amounts of
endotoxin detected at CDC ranging from 47.3 to 429
EU/per 5-liter bag (0.0095 to 0.086 EU/ml; Table 2). Only
one bag had .350 EU [the threshold pyrogenic dose for a
70-kg man (5 EU/kg/hr)]. There was no correlation be-
tween PDS bag endotoxin level and risk of peritonitis.
However, endotoxin was detected more commonly in re-
called than non-recalled lots (5 of 19 vs. 0 of 17, P 5 0.047).
Sixteen lots of PDS were tested for endotoxin and were
among the 34 recalled lots investigated in the manufactur-
er’s phone survey. Of the 16, 8 were independent risk
factors for sterile peritonitis in the logistic regression
model. Measurable endotoxin was found more commonly
in lots that were independent risk factors than in other lots
(4 of 8 vs. 1 of 8, P 5 0.3), but the result was not statistically
significant.
DISCUSSION
Peritoneal dialysis was first used in the treatment of renal
failure in 1923. Infection always has been a serious compli-
cation of peritoneal dialysis. Infectious peritonitis and
Table 1. Potential risk factors for sterile peritonitis, HUP, July 1 to
August 15, 1996
Factor
Total
patients
Number %
case-
patient Risk ratio
P
value
Gender
Male 13 5 (38) —
Female 15 9 (60) 0.64 0.25
Specific lot
received
Lot A
No 22 10 (45) —
Yes 4 4 (100) 2.20 0.1
Lot B
No 23 11 (48) —
Yes 3 3 (100) 2.1 0.2
Received $ 1
recalled lot
No 6 0 —
Yes 22 14 (64) undefined 0.016
Number of recalled
lots received
0 6 0
1 5 1 (20) undefined 0.001a
2 9 7 (78)
3 6 4 (67)
4 2 2 (100)
a P value for trend
Table 2. Endotoxin levels and relative risk for selected lots of
peritoneal dialysis solution
Recalled
lots
Endotoxin
level EU/5
liter bag
Phone Survey HUP cohort
relative
riskOR P value
A 83 1.8 0.001 NS
B ND 2.5 0.0012 2.2
C ND 5.7 0.0001 NS
D 429 3.0 0.0001 NS
E ND 5.7 0.0001 NS
F 47.3 6.1 0.0001 NS
G 62 5.0 0.0001 NS
H 115 1.0a — NS
I ND 2.6 0.0002 NS
Lots are listed if they had detectable endotoxin (N 5 5) or were
independently associated with sterile peritonitis in the manufacturer’s
telephone survey and tested for endotoxin (N 5 8). Abbreviations are:
HUP, Hospital University of Pennsylvania; OR, odds ratio from logistic
regression model; ND, not detected; NS, not significant.
a Lot H was included in the phone survey but was not an independent
risk factor
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catheter-related infections are the most common cause of
morbidity and result in discontinuation of therapy in up to
28% of peritoneal dialysis patients [8–10]. The most com-
mon sign and symptom of peritonitis in peritoneal dialysis
patients are cloudy dialysate effluent and abdominal dis-
comfort, respectively [11, 12]. Sterile peritonitis, which has
a similar clinical picture to bacterial peritonitis, accounts
for , 10% of all episodes of peritonitis [13]. Before 1976,
culture-negative peritonitis was assumed to be due to
concomitant use of antibiotics, a laboratory error, or caused
by a fungus, mycobacteria, virus, or other non-culturable
agent. Although these factors may still apply, in 1977 a
non-infective etiology for sterile peritonitis was docu-
mented during an outbreak traced to an intrinsic contam-
ination of dialysis fluid with endotoxin [2].
In 1980, CCPD was introduced as an alternative mode of
home dialysis [14]. In CCPD, fluid is infused into the
peritoneum during the early morning and left in the
peritoneal cavity during the day. At bedtime, the fluid is
drained and cycling of fluid occurs throughout the night. In
theory, prolonged dwell times and fewer entries into the
sterile system might reduce the risk of infective peritonitis.
On August 16, 1996, the manufacturer recalled 53 lots of
PDS after receiving reports of sterile peritonitis. According
to the manufacturer, only these 53 lots had routine cultures
that showed $ 1 colony forming units of bacteria per
milliliter before terminal sterilization. The organisms cul-
tured from this fluid were Enterobacter taylorae and Kluvera
cryocresceus. These presterilization cultures are done by the
manufacturer as an internal test procedure; when elevated
colony counts are found, general maintenance and cleaning
are increased. However, results of presterilization colony
counts are not a criteria for releasing the lot. Lots are
released if the endotoxin level is , 0.5 EU/ml, which is in
keeping with the industry standards. All PDS lots, including
those recalled, passed this quality assurance test with
endotoxin , 0.5 EU/ml. As a result of this outbreak, the
manufacturer has increased the frequency of equipment
disinfection and filter exchanges.
Our investigation documents a nationwide outbreak of
sterile peritonitis. Our study at one site, HUP, showed that
all case-patients were on CCPD and used 5-liter bags of
PDS. Our results do not implicate one specific lot of PDS.
However, patients who received $ 1 recalled lot of PDS
had a significantly higher risk of sterile peritonitis. Results
of the manufacturer’s telephone survey revealed that nine
lots of PDS were significantly associated with sterile peri-
tonitis in a logistic regression model. Only one of these lots
had a borderline association with sterile peritonitis accord-
ing to our data collected at HUP.
All HUP case-patients were exposed to a subsequently
recalled lot of dialysis solution. However, eight patients
also exposed to a subsequently recalled lot did not become
ill. This may be explained by variability among the lots, bags
of the same lot, endotoxin concentration, and potential to
cause peritonitis. Also, the stock was not always rotated,
that is, the older supplies used before newer ones. Al-
though we determined which patients received subse-
quently recalled lots, it is uncertain whether these lots were
actually used. Patients generally could not report which lots
or boxes they had used before developing peritonitis.
Furthermore, since the risk of sterile peritonitis increased
with receipt of more recalled lots, it is possible that the
non-case-patients had insufficient exposure to the impli-
cated lots.
This is the largest reported outbreak of sterile peritonitis
in the United States. We received reports of episodes from
six states. The manufacturer identified 260 episodes at 515
dialysis centers. However, the manufacturer identified less
than half of the case-patients that we identified at HUP.
This discrepancy may be due to the fact that the manufac-
turer had to rely on information reported by personnel at
the dialysis centers at the time of the phone contact, while
we collected data through an on-site visit. However, the
manufacturer’s phone survey may have significantly under-
estimated the number of episodes of sterile peritonitis
attributable to this product and the extent of the outbreak.
These results suggest that this outbreak was associated
with intrinsic contamination of PDS by a substance re-
leased from bacteria. Endotoxin, which has been implicated
in previous outbreaks of sterile peritonitis, is the likely
cause. All recalled lots of PDS passed the quality control
test of ,0.5 EU/ml, and only some had detectable endo-
toxin. Those with measurable amounts of endotoxin had
ranges from 47.3 to 429 endotoxin units (EU)/per 5-liter
bag, which is equivalent to 0.0095 to 0.086 EU/ml, but well
below the release level of 0.5 EU/ml. CCPD patients
receive up to 15 liters of dialysis fluid daily, over an 8-hour
period, and thus, the maximum dialysate flow rate is
approximately 2 liters/hr. Assuming use of a recalled PDS
with the highest level of endotoxin detected during our
investigation, the maximum exposure of endotoxin to a 70
kg patient would be 172 EU/hr, which is below the recog-
nized threshold pyrogenic dose of 350 EU/hr (5 EU/kg/hr).
Thus, it is possible that endotoxin exposure at levels below
the commonly accepted pyrogenic threshold dose may
cause disease, at least in renal failure patients. This out-
break stopped after the recall of lots of PDS having $ 1
CFU/ml on presterilization cultures. This suggests that
pre-sterilization colony counts may be more sensitive than
the current established endotoxin levels (, 0.5 EU/ml) for
identifying contaminated product, and that colony counts
could be used in conjunction with endotoxin levels as
quality control indicators for CCPD solution.
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